Receptor News and Research

RSS

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

2 Jun 2021

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

A new bioRxiv* preprint reports on the successful use of a protocol to expand SARS-CoV-2-reactive T-cells a thousand-fold.

2 Jun 2021

Newly identified protein could become a target for future cancer treatments

Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer chance of survival. The protein could become a target for future cancer treatments.

2 Jun 2021

New study sheds light on why many COVID-19 patients suffer from hypoxia

A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues.

2 Jun 2021

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

A recent study conducted by a team of scientists in the Netherlands has revealed that while severely affected hospitalized COVID-19 patients and vaccinated individuals are capable of neutralizing the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2, a significant proportion of non-hospitalized patients with less severe COVID-19 remain susceptible to these viral variants.

2 Jun 2021

Could semen quality indicate SARS-CoV-2 insult susceptibility in polluted areas?

In a recent review in Environmental Science and Pollution Research, Italian researchers focused on “the evidence that correlates the degree and type of pollution with the increased susceptibility of many countries to this pandemic and proposes human semen as an early marker of the environmental health and the general health of individuals.” Their observations are based on a robust body of experimental evidence.

2 Jun 2021

New vaccine candidate with RBD and N protein targets protects against SARS-CoV-2 in preclinical trials

A recent study published in the journal Science Advances, explores the immunization of RBD with the P2 epitope of tetanus toxoid, to enhance its immunogenicity, and also tests the benefit of N protein in the vaccine.

2 Jun 2021

Novel antibody engineering approach

Scientists from the Johns Hopkins University School of Medicine, USA, have recently developed an Antibody Display technology by grafting the second extracellular domain of tetraspanin12 (Tspan12EC2) and the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein on the heavy chain complementarity-determining region 3 (CDR3).

2 Jun 2021

Researchers identify kite-shaped molecules that block SARS-CoV-2 cell entry after attachment

They have identified a group of kite-shaped compounds that are highly specific to SARS-CoV-1 and SARS-CoV-2. These compounds demonstrate high potency in inhibiting SARS-CoV-2 infection at early entry steps. The study is currently available on the bioRxiv* preprint server.

2 Jun 2021

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Researchers from Ontario, Canada, recently conducted a prospective observational study to determine the SARS-CoV-2 antibody response in chronic hemodialysis patients following one vs. two doses of the BNT162b2 COVID-19 vaccine. The results were compared to health care worker controls and convalescent serum.

1 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Study reveals why mothers take extra risks to protect their children

It might seem like a given that mothers take extra risks to protect their children, but have you ever wondered why? A new study led by Kumi Kuroda at the RIKEN Center for Brain Science (CBS) in Japan shows that in mice, this and other nurturing behaviors are driven in part by neurons in a small part of the forebrain that contain a protein called the calcitonin receptor.

1 Jun 2021

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

Researchers identify common epitopes across SARS-CoV-2 viral variants

While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.

1 Jun 2021

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

Plexin-A1 gene plays a more extensive role in brain development, study shows

Study by the University of Bonn shows that mutations of the investigated gene manifest in different patterns of inheritance.

31 May 2021

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

A recent report by a team of researchers focused on the extent of convergent evolution in the SARS-CoV-2 spike (S) protein. The report confirms that top SARS-CoV-2 lineages of concern have the most convergent spike protein mutations. This indicates their fundamental adaptive advantage.

31 May 2021

Receptor News and Research

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

Newly identified protein could become a target for future cancer treatments

New study sheds light on why many COVID-19 patients suffer from hypoxia

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Could semen quality indicate SARS-CoV-2 insult susceptibility in polluted areas?

New vaccine candidate with RBD and N protein targets protects against SARS-CoV-2 in preclinical trials

Novel antibody engineering approach

Researchers identify kite-shaped molecules that block SARS-CoV-2 cell entry after attachment

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Study reveals why mothers take extra risks to protect their children

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers identify common epitopes across SARS-CoV-2 viral variants

Using Sotrovimab to treat COVID-19 early

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Plexin-A1 gene plays a more extensive role in brain development, study shows

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News